v3.26.1
SCHEDULE OF FAIR MARKET VALUE OF ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) - NDPD Pharma Inc [Member] - USD ($)
Oct. 25, 2024
Oct. 01, 2024
Business Combination [Line Items]    
License Agreement for 33% of the value in a single indication (Covid-19)   $ 8,190,000
Stock in Bioxytran (14,085,410 Preferred shares)   7,660,000
Patent (WO2022099052A1) including free use of PHGG based compounds for therapeutical use in Covid-19: including, but not limited to Clinical Trials, Manufacturing and Distribution.  
Patent (WO2023178228A1) including free use of PHGG based compounds for therapeutical use in 60+ viral infections: including, but not limited to Clinical Trials, Manufacturing and Distribution.  
Bank assets, Debt and Expenses Assumed   (10,282)
Official valuation   $ 15,848,987
Assumed value $ 12,459,658  
Common Stock [Member]    
Business Combination [Line Items]    
Assumed value 289,774  
Preferred Stock [Member]    
Business Combination [Line Items]    
Assumed value $ 12,169,884